M
edical schools have too often taught-actively, or passively by example-acquiescence to the increasing trends toward medicine as a business rather than teaching resistance to those trends in a manner consistent with medicine as a profession. A rapidly growing amount of research has documented the deleterious effects of this business model on doctors and/or patients. But except in rare instances, medical curricula for students or residents neither include in-depth discussions of such research nor map out strategies for resisting and reversing these dangerous trends, including encouraging more research in these areas. As we approach the 100th anniversary of the 1910 Flexner Report, which revolutionized and rationalized medical education, we must heed his admonition to apply the scientific method to all dimensions of medicine, including elucidating evidence for the destruction of medicine and medical education by market forces. Ironically, the revolution in medical education occasioned by that report included the evidence-based elimination of a large number of poor quality medical schools being run on a forprofit basis. The new model that evolved emphasized a non-commercial ethic of professionalism and service, but this model is now in jeopardy.
Health Services and Medical

Education
Among developed countries, the United States is unique in having a substantial proportion of health services delivered by for-profit businesses. Research has documented that the quality of care is worse in for-profit HMOs, kidney dialysis centers, nursing homes, and hospitals than in non profits, just as Flexner documented poor quality education in for-profit medical schools. We are also the only country in the world in which the predominant mode of health care delivery is forprofit managed care companies, squeezing doctors and patients into shorter visits and less care, in too many instances simply to pay CEOs and stockholders more. The managed care industry has driven teaching hospitals into an entrepreneurial response that undermines the critical missions of teaching as well as professionalism and service.
Resistance to these dangerous directions is needed to diminish the incursions of for-profit medical care. Research and teaching concerning the poorer quality of for-profit care would add to the atmosphere and strength of resistance.
But there are two concomitant and similarly unique aspects of this marketdriven system, now caused and controlled by private insurance companies with an increasing amount of for-profit care. First is the failure to provide health care as a right to all citizens, leaving one seventh of our population, about 40 million people, without health insurance. Second is the failure of our government to provide low cost medical education to all who are qualified to enter medical school because of the lack of an overall national policy to pay for medical education.
Medical schools should end the general silence on the absolute necessity for a single payer, government-financed health insurance plan by teaching students its unique advantages. In addition, a coalition of medical students and faculty should be leading a national effort for government subsidy of a much larger part of medical education so that socioeconomic-class-based discrimination does not continue to pose barriers for many to attend medical school and so that medical teaching institutions and their faculties are on firmer financial footing, less dependent on commercial ventures. Another important advantage of a single government payer for all medical setvices would be to overcome the perpetual private health insurance industry's resistance to such a subsidy.
The Pharmaceutical Industry and Medical Schools
Another important area in which medical educators need to be offering much more resistance involves the pharmaceutical industry. Medical journal articles that distort the actual results of clinical trials concerning drugs or other medical products, ghost-written articles, delayed articles and publication bias as a result of industry pressure have led to guidelines endorsed by editors of 13leading international medical journals. The cause was succinctly stated in the prologue to the guidelines. "As CROs (contract research organizations) and academic medical centers compete head to head for the opportunity to enroll patients in clini-
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cal trials, corporate sponsors have been able to dictate the terms of participation in the trial---terms that are not always in the best interests of academic investigators, the study participants, or the advancement of science generally."
But the publication step is at the end of the research process, and much damage can be done by then, especially because many of the most alarming findings of drug-company-sponsored research are not published. Medical schools should prohibit equity interest in drug companies by academic researchers who are doing clinical trials. The broader issue is that drug companies should fund clinical trials but have no control over their design and implementation, the interpretation of data, or publication. More than merely a change in journal publication policy is needed for this to occur, and medical schools need to be at the forefront of advocating such a change.
There has been an increase in deals between medical schools and pharmaceutical or medical device manufacturers to develop products under exclusive arrangements that will generate income for the medical schools and faculty members. The formation of small companies involving faculty to develop products is, at the least, a drain on teaching and other noncommercializable research efforts.
There is good evidence that money from drug companies or contacts with them can influence faculty decisions regarding hospital formulary additions. There is also widespread drug company funding of hospital rounds, and contact with drug reps is allowed in many academic medical teaching centers. Attendance at free drug-companysponsored dinners, sports events, and thinly disguised marketing efforts labeled as research are often viewed as an acceptable norm. Contrary to a recent statement by former AMA President Alan Nelson, MD, that "Ongoing interaction and strong communication between physicians and [the pharmaceutical] industry is vital for good patient care," many of the best physicians have little if any contact with this industry.
The need for resistance to these influences has been articulated by the eminent medical historian and ethicist, 
Medical School Courses In
Research-based Activism In many ways, the public is more educated about the evils and dangers of market medicine than is the medical profession. In order for a joint effort of doctors, working with patients, to succeed in supplanting the current market-based system and restoring professionalism to medicine and to the doctor patient relationship, there needs to be a radical shift in medical education to include such information.
We in the Public Citizen Health Research Group have been involved in helping to start several medical school courses in research-based activism that provide students with examples of evidence about such problems with our health care system. In some courses, students are taught to design protocols or even execute research projects that would add information and presumably help to cause changes in these areas. Information about one of the first such courses, at Case Western Reserve University School of Medicine, is available on a web site that is being expanded to include information about other such courses at Johns Hopkins, NYU, and other schools, www.citizen.org/hrg/activistcourses. Over the 30 years since the Health Research Group was begun, 20 medical students and 11 residents in preventive medicine have done rotations with us, lasting from two months to a year. In addition, we have collaborated with 35 post-residency physicians since 1996 on research-based activism projects. Many of the projects they worked on have resulted in bans or warnings on prescription drugs and restrictions in the amounts of dangerous chemicals workers are exposed to. The results of some of these projects have been published, and our web site, www.citizen.org/hrg, includes the full details of many of the most recent efforts at research-based change.
Conclusion
As long as the predominant vision of medical educators is acquiescence to market forces instead of resistance and constructive change, market medicine will thrive, to the detriment of doctors and patients alike, and medicine, as a profession, will suffer, along with the simultaneous erosion of the doctor patient relationship.
Flexner taught evidence-based-resistance and change. The lesson of the elimination of for-profit medical schools must not be lost, and a concerted effort by medical educators and our students and residents as well as patients to eliminate all for-profit health services and to reduce medical school dependence on commercial activities must be undertaken. Under the banner of "Get Smart," Business Week points out that "for every dollar the country spends on drugs, it wastes another dollar fixing medical problems caused by those same drugs. Doctors and hospitals are prescribing the wrong drugs to many and too many drugs to others."
The editorial goes on to say that the extraordinary rise in drug spending is not primarily due to cancer and AIDS drugs, used by a small fraction of the population, "but by cholesterol-lowering heart medications, psychiatric medications, and painkillers used by tens of millions of people. Exercise and a good diet can help reduce heart disease, diabetes, anxiety and some pain." "Get Tough" introduces their accurate accusation that the drug industry is "gaming the patent system to stymie competition." Under current law, the Food and Drug Administration is compelled to "freeze generic versions of drugs for 30 months if a drug company complains that the generic infringes on its patent. Two and a half years is a ridiculous wait; it should be shortened to three months." "Get Honest" attacks drug advertising by stating that 1V pharmaceutical advertising "promotes high-priced new drugs with marginal [if any] improvements over cheaper generic versions. The FDA should crack down harder on misleading ads."
Although we agree with all of the above, we would add that there needs to be government-negotiated prices or price controls, as currently exist in every other industrialized country in the world. For now, this would benefit Medicare recipients for whom a drug benefit is unlikely without such controls, which now benefit those in the military and Veterans' Administration programs that purchase pharmaceuticals at deep discounts. But otherwise, not bad, Business Week. 
Product Recalls
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The recalls noted here reflect actions taken by a finn to remove a product from the market. Recalls may be conducted on a finn's own initiative, by FDA request, or by FDA order under statutory authority. A Class I recall is a situation in which there is a reasonable probability that the use of or exposure to the product will cause serious adverse health consequences or death. Class II recalls may cause temporary or medically reversible adverse health consequences. A Class III situation is not likely to cause adverse health effects. If. you have any of the drugs noted here, label them Do Not Use and put them in a secure place until you can return them to the place of purchase for a full refund. You can also contact the manufacturer. If you want to report an adverse drug reaction to the FDA, call (800) FDA-1088. The FDA web site is wwwfda.gov. Unless these important codes are acted upon, adherence to them will be dangerously low. The only way to accomplish this is to revoke the license of any physician who so participates in any way in the execution of a person. Dr. Pintz is the first such physician whose identity has come to my attention. Unless the New Mexico Board takes immediate action to suspend and revoke his license if he refuses to reverse the violent course of action which he has facilitated, the Board will have failed in its responsibility to uphold the legal and ethical principles under which it must operate.
Class I Recalls
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Epilogue:
The NM Board decided to call Dr. Pintz and warn him that unless he reversed his decision to participate in the lethal injection by facilitating the acquisition of the necessary drugs, the Board might take an action against his license. Dr. Pintz recanted and the drugs which had been obtained with his permission were returned. Unfortunately for the person on death row, the drugs were nevertheless obtained without the involvement of Dr. Pintz and the execution was carried out. An important precedent was set, however, wherein a state medical board has successfully threatened a doctor-licensee against participation in an execution because the board correctly sees this as a violation of the state medical practice act as discussed in the above letter by Dr. Wolfe. The study was conducted by researchers from the University of California, San Francisco, Department of Medicine, who collected information from a random sample of almost 5,000 Americans, 70 or older, with and without drug coverage, who regularly used prescription medicines. Even one of three risk factors-ethnicity, income and out-of-pocket drug costs of more than $100 a month-made it significantly more likely that people without prescription drug coverage would be forced to restrict their use of medications due to cost.
In the study, 20.9 percent of minority subjects, 15.6 percent of those with annual incomes under $10,000 and 13.4 percent of those with out-of-pocket prescription drug costs of more than $100 per month experienced medication restriction due to cost. Looked at from a different perspective, low-income study participants lacking prescription drug insurance were about 15 times more likely to limit their use of prescription drugs than low-income participants with full coverage.
Thus, in the absence of a prescription drug benefit, some of the country's most vulnerable seniors are most likely to go without the medicines they may need to maintain their health. The study's authors note that previous studies have shown that "policies designed to limit medication use may have serious consequences for patients' health, resulting in increased emergency department visits, nursing home admissions, [and] use of emergency mental health services." "These findings bring to the fore the idea that when you judge societies by how they treat their most vulnerable members, the United States ranks very low," said Dr. Sidney M. Wolfe, director of Public Citizen's Health Research Group reacting to the study. "Our country fails to provide health insurance for about one-seventh of our population and fails to provide prescription drug · coverage for millions of Medicare-cov~ ered older Americans who cannot afford to purchase drug coverage on their own."
The results of the study are consistent with a November 20, 2001 Harris Poll of a random sample of 1,010 adult Americans that found 39 percent of people with annual incomes of less than $15,000 a year had not filled a prescription for medicine in the previous 12 months.
Dr. Michael Steinman, the lead author of the study, works in the Department of Medicine, San Francisco Veterans Affairs Medical Center and at the University of California, San Francisco.
A copy of the Harris poll is available T he front page of the Globe on January 1 had a story about the failure of the state's Board of Medicine to discipline an orthopedic surgeon with a long history of malpractice. Similar stories appear from time to time. Is the board as ineffectual in its disciplining of incompetent doctors as these stories would have you believe? And if the charge is even partly true, why is that? Having recently retired after six years on the board, I can offer some answers.
First, while not nearly as feckless as the news reports imply, the board is not providing the kind of protection against substandard practitioners that the public has a right to expect. Massachusetts is not different from many other states in this respect, but that doesn't justify its poor performance. So the answer to the first question is a qualified yes.
There are too many substandard practitioners in this state who may never even be identified, let alone reeducated or disciplined, including some who endanger their patients and ought to be removed from practice. There are many explanations, the most obvious and indisputable of which are the failure of state government to provide adequate financial support and its habit of allowing cronyism and patronage to influence appointments, policies, and operations.
Almost all of the board's budget is offset by medical licensure fees collected by the state, so the state makes essentially no contribution. The board is left underfunded, understaffed, and unable to meet all of its responsibilities. The five physicians and two "public" members on the board are overworked and vastly underpaid (they get $35 for each day they work). In addition, its professional quality and independence are often compromised by political interference that goes beyond the legitimate claims of accountability.
At least as great an impediment to the board's effectiveness are the restrictions of its actions by lawyers and some ill-conceived provisions of the law. Hospitals hire lawyers and administrators to protect them from being sued. They call it "risk management."
When the focus is on patient safety and prevention of medical mishaps, "risk management" is fine, but too often it simply becomes a legally managed cover-up of the facts. Board investigations of alleged malpractice or substandard care are often frustrated by the reluctance of hospitals to cooperate "on advice of counsel."
Such cover-up gains support from a 1987 ruling of the state's Supreme Judicial Court that the proceedings of hospital peer review committees are protected from disclosure.
Another legal obstruction to effective disciplinary action is the widely held conception that medical licensure, once granted, is the private property of the licensee and therefore can be limited or revoked only through a full legal process. Board hearings are conducted as if they were courtroom trials, with lawyers doing most or all of the talking for their physician clients. Often, testimony submitted by both sides is evaluated in separate hearings by administrative magistrates.
Contested decisions are reviewed by the courts.
But a medical license is more a privilege than a property right. It is granted and renewed by the state only after the applicant has satisfied requirements established by professionals who, while acting under state authority, are following standards that can only be established and interpreted by the profession. The application of legal procedures to medical disciplinary proceedings always delays and often stymies the process, and it risks producing a result that is medically unsound. By making licensure a property right and relying on legal process rather than on the medical judgment of the board and its consultants, the state is in effect placing the business interests of physicians ahead of the welfare of patients.
Last but not least, the Massachusetts board, like state boards generally, has to contend with the suspicion and timidity of most practicing physicians, who understandably are reluctant to become involved in an investigation of a colleague's alleged misbehavior. The board is often frustrated by its failure to gain testimony from an accused physician's colleagues and by the unwillingness of even its own expert witnesses to make judgments about the competence of a physician.
Practitioners who are whistle-blowers have little to gain from what is often a major investment of time and effort while they risk the ostracism of colleagues and possible countersuits by the accused. At the least they ought to be protected against such legal reprisals.
Given all these difficulties, the Massachusetts board does well to accomplish what it has, but under present constraints it cannot do a really good job of protecting the public interest. A good way to start improving things would be to give the board adequate financial support and greater independence and authority. Most of all, it needs some relief from the paralyzing notion that medical licensure is primarily a property right that takes precedence over public safety.
•••
The problems with the Massachusetts Medical Board, described by former Board member Dr. Arnold Reiman, apply to a large proportion of medical boards in the United States. In our rankings of state medical boards, based on the rate of serious disciplinary actions 1000 physicians, Massachusetts has consistently been among the poorest performing boards in the country. For serious disciplinary actions it took in 2000, the state was 45th in the country and between 1991 and 2000 its rank was never higher than 37th and was as low as 48th.
FDA Action on Red Cross Long Overdue
A year ago, Public Citizen requested the U.S. Food and Drug Administration (FDA) to ask that the American Red Cross (ARC) be held in contempt of court because of longstanding, dangerous practices that are jeopardizing the safety of the U.S. blood supply. On December 13, 2001, the FDA finally made that request.
While we are pleased the government took action, it is long overdue, and we urge the court to act swiftly. Records indicate that the Red Cross has not come into compliance with a 1993 consent decree or with U.S. laws and regulations concerning blood and blood products.
The importance of having a safe blood supply cannot be overstated. The American public relies heavily on the Red Cross blood supply, and patients should know that when they receive blood, it will not be tainted. Records indicate that the ARC has improperly released blood products containing cytomegalovirus, a virus that can cause blindness in newborns. Also, FDA inspectors found that blood donors had incorrect histories and that Red Cross staff failed to follow test kit instructions for HN. Although the FDA insists the blood supply is safe, these findings cause grave concern. If proper procedures are not followed, it is only a matter of time before someone is seriously harmed. That would be inexcusable, particularly given the fact that the government has known about the Red Cross' violations for well over a decade. Even the ARC's former president, Dr. Bernadine Healy, said in an August 14, 2000, meeting that she found the FDA's findings "alarming" and that the severity of the situation held the potential for "grave impact" to patients, court records show.
We strongly support the efforts to hold the Red Cross in contempt of the consent decree. Unfortunately, given the lengthy history of this case, the fines that would accompany a contempt of court citation appear to be the only way the Red Cross will respond. The Canadian decision was reached after a risk assessment concluded that these products pose a serious health risk. Adverse events including stroke, heart attacks, heart rate irregularities, seizures, psychoses and deaths have been reported in association with the use of some products containing Ephedra or ephedrine.
Canadians Begin Recall of Dangerous
This recall deals with the following types of Ephedra or ephedrine products:
1. Products having a dose of more than 8 milligrams of ephedrine or with a label recommending more than 8
You should not use Ephedra or ephedrinecontaining drugs milligrams per dose or 32 milligrams per day and/or are labeled or implied for use exceeding seven days.
2. All combination products containing Ephedra or ephedrine together with another stimulant such as caffeine and other ingredients which might increase the effect of Ephedra or ephedrine in the body.
3. Products with labeled or implied claims for appetite suppression, weight loss promotion, metabolic enhancement, increased exercise tolerance, body-building effects, increased energy or wakefulness, or other stimulant effects.
This action by the Canadian authorities is a rational regulatory policy to protect their citizens from dangerous drug supplements. In this country, the public must face alone the irrationality of an unregulated market for drug supplements because of the Dietary Supplement Health and Education Act enacted in 1994.
What You Can Do
You should not use Ephedra or ephedrine-containing drugs. They are dangerous and without a legitimate medical use.
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The AMA Does It Again T he American Medical Association (AMA) has added another chapter to the seemingly endless succession of extremely poor, dangerous choices for executive vice president of the organization. The announcement that the new AMA chief executive, Dr. Michael Maves, is the former president of Consumer Healthcare Products Association (CHPA), the trade association representing the herbal, dietary supplement and over-the-counter drug (OTC) industries (presumably with the approval oftheAMA'sBoardofTrustees), threatens to bring this troubled and dying organization from the early part of the 21st century back to the 19th century. In that earlier era, before medicines had to be proven safe and effective before being sold, patent medicines, some of which were referred to as snake oils, ruled the roost. To the extent that CHP A now represent<; the herbal/dietary supplement drug companies, and to the extent that a large proportion of these products lack evidence of safety and efficacy, this appears to be another deadly embrace for the AMA.
Even in the realm of OTC drugs, CHP A funded and signed off on the design of a Yale study on the decongestant and weight reduction drug, PPA (phenylpropanolamine). But when the study showed a significant increase in hemorrhagic strokes in people using products containing the drug, CHP Aunder the leadership of Dr. Mavesdenounced the study. In the 1980s, the predecessor to CHPA, the Non-Prescription Drug Manufacturers Association, was instrumental in delaying the addition of warning labels on aspirin concerning the increased risk ofReye's Syndrome in children with flu or chicken lri>Vt'HO pox who took aspirin. As a result of the delay, hundreds more children died or sustained brain damage.
We urge all physicians who still cling to their AMA membership--despite its embrace of the Sunbeam scandal (an uncritical proposed endorsement of products under the leadership of Dr. John Seward), the real estate scandal (under the leadership of Dr. James Sammons) and the recent predictably poor leadership of Dr. E. Ratcliffe Anderson--to resign from this dying organization, which once represented more than two-thirds of American doctors but soon will represent less than one-third. The hundreds of dollars of patients' money, which goes to pay for annual dues, could be better spent. Subscriptions to excellent medical journals such as the journal oftheAmerican Medical Association are available to non-members as well as members. 
